文献速递类风湿关节炎其他结缔组织病

利妥昔单抗挽救治疗进展性类风湿关节炎相关间质性肺病的真实世界长期疗效

Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease.
PubMed 文献 · Semin Arthritis Rheum · 2020-08-30

本研究为纵向回顾性观察研究,纳入31例对糖皮质激素和传统合成改善病情抗风湿药或免疫抑制剂治疗后仍进展的RA-ILD患者,接受至少2个周期利妥昔单抗治疗并随访至少12个月。结果显示利妥昔单抗可逆转肺功能下降,1年时%pFVC和%pDLCO显著改善,且泼尼松剂量显著减少,26%患者可停用泼尼松。

要点

  • 利妥昔单抗可逆转进展性RA-ILD患者的肺功能下降,1年时%pFVC和%pDLCO显著改善。
  • UIP和非UIP型患者肺功能均显著改善,2年时疗效维持。
  • 泼尼松剂量显著减少,26%患者可停用泼尼松。

核心结论

  • 利妥昔单抗作为挽救治疗对相当比例的传统治疗无效的进展性RA-ILD患者有效。

研究设计与样本

  • 纵向回顾性观察研究,纳入31例因持续进展性ILD在接受糖皮质激素和csDMARDs或免疫抑制剂治疗后开始利妥昔单抗治疗的RA-ILD患者。
  • 所有患者接受至少2个周期利妥昔单抗治疗并评估至少12个月,期间csDMARDs或免疫抑制剂治疗保持不变。

主要发现

  • 利妥昔单抗治疗前,自ILD诊断(中位21个月)起%pFVC和%pDLCO的平均下降分别为-16.5%和-19.7%。
  • 治疗1年后,%pFVC较基线改善+8.06%(95%CI:-10.9至-5.2;p<0.001),%pDLCO改善+12.7%(95%CI:-16.3至-9.1;p<0.001)。
  • 泼尼松中位剂量显著减少,26%的病例可停用泼尼松。
  • UIP和非UIP型患者肺功能参数均显著改善。
  • 完成2年治疗的25例患者(80.6%)中,1年时肺功能改善维持:%pFVC +11.2%(95%CI:-15.6至-6.8;p<0.001),%pDLCO +14.8%(95%CI:-19.3至-10.3;p<0.001)。

临床怎么用

  • 对于传统治疗无效的进展性RA-ILD患者,利妥昔单抗可作为挽救治疗选择。
  • 治疗期间需监测肺功能、泼尼松剂量及不良事件,不良事件发生率较高。

局限性

  • 回顾性观察性研究,样本量较小(31例),缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease (RA-ILD) in whom more conventional therapy has failed. METHODS: Longitudinal retrospective observational study of a cohort of patients with RA-ILD that started treatment with RTX due to ongoing progressive ILD despite treatment with glucocorticoids and csDMARDs or immunosuppressants (IS). All patients were treated with two or more cycles of RTX and evaluated for at least 12 months. Ongoing therapy with csDMARDs or IS remained unchanged. RESULTS: Thirty-one patients were analyzed. Before initiation of RTX the mean decline (delta) in %pFVC and %pDLCO from the ILD diagnosis (median 21 months) was -16.5% and -19.7%, respectively. After 1 year of treatment, RTX was able to reverse the decline of pulmonary function test (PFTs) parameters: ∆%pFVC +8.06% compared to baseline (95% CI: -10.9 to -5.2; p<0.001) and ∆%pDLCO +12.7% (95% CI: -16.3 to -9.1; p<0.001). In addition, there was a significant reduction in the median dose of prednisone, and it could be suspended in 26% of cases. Dividing the population into UIP and non-UIP patterns, we observed a significant increase in PFTs parameters in both groups. In the 25 patients (80.6%) that completed 2 years of treatment, the statistically significant amelioration in PFTs parameters observed at one year was maintained: ∆%pFVC +11.2% (95% CI: -15.6 to -6.8; p<0.001) and ∆%pDLCO +14.8% (95% CI: -19.3 to -10.3; p<0.001). At the end of the follow-up period (median 32 months; IQR 25th-75th 26-64), only 23 of the 31 patients (74.2%) were still undergoing treatment with RTX: in 3 cases (10%) it was stopped due to adverse events, in another 3 (10%) treatment failed ultimately requiring a lung transplant, and 2 patients (6%) died due to progression of the ILD and infectious complications. The frequency of adverse events reached 32% of cases. CONCLUSION: Based on our results, RTX appears to be effective as rescue therapy in a considerable proportion of patients with progressive RA-ILD unresponsive to conventional treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Narváez J, Robles-Pérez A, Molina-Molina M, et al. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Semin Arthritis Rheum. 2020. PMID: 32906025. doi:10.1016/j.semarthrit.2020.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。